| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fatima Abu-Tair, Jürgen Kopitz, Niels Bergeman. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. Journal of clinical psychopharmacology. vol 26. issue 6. 2007-02-07. PMID:17110831. |
clozapine augmented with aripiprazole in 5 patients with schizophrenia. |
2007-02-07 |
2023-08-12 |
Not clear |
| Wlodzimierz K Chrzanowski, Ronald N Marcus, Anne Torbeyns, Margaretta Nyilas, Robert D McQuad. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. vol 189. issue 2. 2007-02-05. PMID:17058105. |
effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. |
2007-02-05 |
2023-08-12 |
Not clear |
| Wlodzimierz K Chrzanowski, Ronald N Marcus, Anne Torbeyns, Margaretta Nyilas, Robert D McQuad. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. vol 189. issue 2. 2007-02-05. PMID:17058105. |
to compare the long-term efficacy and safety of aripiprazole with olanzapine in patients with either acute relapsing or chronic, stable schizophrenia. |
2007-02-05 |
2023-08-12 |
Not clear |
| Manan Shastri, Lakshmiramana Alla, Manga Sabaratna. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. Journal of psychopharmacology (Oxford, England). vol 20. issue 6. 2007-01-26. PMID:16891339. |
aripiprazole is a novel antipsychotic quinolone derivative that has been approved for the treatment of schizophrenia in adults. |
2007-01-26 |
2023-08-12 |
Not clear |
| Manan Shastri, Lakshmiramana Alla, Manga Sabaratna. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. Journal of psychopharmacology (Oxford, England). vol 20. issue 6. 2007-01-26. PMID:16891339. |
issues related to the usefulness of aripiprazole in the management of schizophrenia and challenging behaviour in people with intellectual disabilities are also discussed. |
2007-01-26 |
2023-08-12 |
Not clear |
| Manan Shastri, Lakshmiramana Alla, Manga Sabaratna. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. Journal of psychopharmacology (Oxford, England). vol 20. issue 6. 2007-01-26. PMID:16891339. |
aripiprazole was well tolerated and effective in each of the cases and appears to be a safe and efficacious alternative in the management of patients with both intellectual disabilities and schizophrenia. |
2007-01-26 |
2023-08-12 |
Not clear |
| Margarita García-Amador, Isabella Pacchiarotti, Marc Valentí, Raul F Sanchez, Jose M Goikolea, Eduard Viet. Role of aripiprazole in treating mood disorders. Expert review of neurotherapeutics. vol 6. issue 12. 2007-01-24. PMID:17181424. |
randomized studies have demonstrated the efficacy of aripiprazole compared with placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, treatment of acute mania, and prevention of manic relapse in patients who responded to the drug during a manic episode. |
2007-01-24 |
2023-08-12 |
Not clear |
| D S J S Fernald, R T van Dellen, J E Hovens, A J M Loone. Aripiprazole in chronic schizophrenia: experiences in daily practice. Acta psychiatrica Scandinavica. vol 114. issue 4. 2007-01-10. PMID:16968370. |
aripiprazole in chronic schizophrenia: experiences in daily practice. |
2007-01-10 |
2023-08-12 |
Not clear |
| Karen E Moeller, Theresa I Shireman, Barry I Lisko. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. The Journal of clinical psychiatry. vol 67. issue 12. 2007-01-09. PMID:17194273. |
relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. |
2007-01-09 |
2023-08-12 |
Not clear |
| Karen E Moeller, Theresa I Shireman, Barry I Lisko. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. The Journal of clinical psychiatry. vol 67. issue 12. 2007-01-09. PMID:17194273. |
the primary objective of this study was to compare relapse rates among patients with schizophrenia who were switched to aripiprazole with those who switched to a second-generation antipsychotic (sga) from another antipsychotic. |
2007-01-09 |
2023-08-12 |
Not clear |
| Marc De Hert, Linda Hanssens, Ruud van Winkel, Martien Wampers, Dominique Van Eyck, Andre Scheen, Joseph Peusken. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes care. vol 29. issue 10. 2007-01-05. PMID:17003321. |
reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. |
2007-01-05 |
2023-08-12 |
Not clear |
| Marc Ziegenbein, Georg Wittmann, Stefan Krop. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clinical drug investigation. vol 26. issue 3. 2007-01-03. PMID:17163242. |
aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. |
2007-01-03 |
2023-08-12 |
Not clear |
| Andrew J Cutler, Ronald N Marcus, Sterling A Hardy, Amy O'Donnell, William H Carson, Robert D McQuad. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS spectrums. vol 11. issue 9. 2006-12-13. PMID:16946694. |
the efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. |
2006-12-13 |
2023-08-12 |
Not clear |
| Andrew J Cutler, Ronald N Marcus, Sterling A Hardy, Amy O'Donnell, William H Carson, Robert D McQuad. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS spectrums. vol 11. issue 9. 2006-12-13. PMID:16946694. |
efficacy and safety of aripiprazole administered at doses lower than those previously studied systematically were investigated in patients with acute exacerbation of schizophrenia. |
2006-12-13 |
2023-08-12 |
Not clear |
| H G El-Sayeh, C Morganti, C E Adam. Aripiprazole for schizophrenia. Systematic review. The British journal of psychiatry : the journal of mental science. vol 189. 2006-12-05. PMID:16880478. |
aripiprazole for schizophrenia. |
2006-12-05 |
2023-08-12 |
Not clear |
| H G El-Sayeh, C Morganti, C E Adam. Aripiprazole for schizophrenia. Systematic review. The British journal of psychiatry : the journal of mental science. vol 189. 2006-12-05. PMID:16880478. |
aripiprazole is an atypical antipsychotic that is reported to be effective in the treatment of schizophrenia. |
2006-12-05 |
2023-08-12 |
Not clear |
| Kalyan Bachu, Darshan Godkar, Anna Gasparyan, Padmini Sircar, Mila Yakoby, Selvanayagam Niranja. Aripiprazole-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). American journal of therapeutics. vol 13. issue 4. 2006-12-01. PMID:16858173. |
aripiprazole is a newer atypical antipsychotic agent used for effective treatment of schizophrenia. |
2006-12-01 |
2023-08-12 |
Not clear |
| Kalyan Bachu, Darshan Godkar, Anna Gasparyan, Padmini Sircar, Mila Yakoby, Selvanayagam Niranja. Aripiprazole-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). American journal of therapeutics. vol 13. issue 4. 2006-12-01. PMID:16858173. |
we present the first reported case of siadh caused by aripiprazole in a patient with history of schizophrenia without other precipitating factors to explain hyponatremia or siadh. |
2006-12-01 |
2023-08-12 |
Not clear |
| R Andrezina, R N Marcus, D A Oren, G Manos, E Stock, W H Carson, R D McQuad. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Current medical research and opinion. vol 22. issue 11. 2006-12-01. PMID:17076982. |
intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. |
2006-12-01 |
2023-08-12 |
Not clear |
| R Andrezina, R N Marcus, D A Oren, G Manos, E Stock, W H Carson, R D McQuad. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Current medical research and opinion. vol 22. issue 11. 2006-12-01. PMID:17076982. |
a sub-population analysis of 325 patients with agitation (positive and negative syndrome scale excited component [pec] score > or = 15 and < or = 32; score of > or = 4 on > or = 2 items) associated with schizophrenia in a randomized, double-blind study investigating the efficacy and tolerability of intramuscular (im) aripiprazole 9.75 mg, im haloperidol 6.5 mg, or im placebo and the transition to oral therapy. |
2006-12-01 |
2023-08-12 |
Not clear |